PA.Sig: A Cell Death Program-Based Prognostic Signature for Glioma

PA.Sig, a pyroptosis–apoptosis–associated gene signature, stratifies glioma patients into high- and low-risk groups with significantly different overall survival. The signature was developed using transcriptomic and clinical data from the TCGA-GBMLGG cohort and validated externally. Huaichao Zhang published this research on figshare in May 2026.

Use Cases

• Prognostic risk stratification of glioma patients based on the described cell death gene signature.
• Analysis of tumor immune microenvironment features, such as immune dysfunction and exhaustion, associated with the PA.Sig risk groups.
• Investigation of malignant cell states, including MES-like and AC/MES-like states, linked to the inflammatory cell death landscape.
• Studying the relationship between somatic mutation burden and coordinated cell death programs in glioma.

Strengths

• Signature was constructed and validated using data from the TCGA-GBMLGG cohort and external validation cohorts.
• Analysis includes single-cell RNA sequencing data to delineate malignant cell states and intercellular communication.
• Functional validation was conducted in glioma cell lines treated with chemotherapeutic agents.

Limitations

• The dataset is a 300.3 KB PDF, which is a small document; the underlying raw data files are not directly provided.
• Column-level documentation and sample data are unavailable, requiring manual inspection after download.
• Row count for any underlying data is unknown, limiting suitability assessment for large-scale analysis.

Provenance

Source

figshare, authored by Huaichao Zhang.

Collection Method

Integrative survival modeling of transcriptomic and clinical data from TCGA-GBMLGG and external cohorts.

Freshness

Last updated 2026-05-21 04:39:04; freshness should be verified.